Dr Camille Ettelaie's Outputs (4)

Low molecular weight heparin downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-κB (2011)
Journal Article
Ettelaie, C., Fountain, D., Collier, M. E. W., ElKeeb, A. M., Xiao, Y. P., & Maraveyas, A. (2011). Low molecular weight heparin downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-κB. Biochimica et Biophysica Acta (BBA): Molecular Basis of Disease, 1812(12), 1591-1600. https://doi.org/10.1016/j.bbadis.2011.09.007

Treatment of cancer patients with low molecular weight heparin (LMWH) appears to have beneficial effects. In this study, the influence of low molecular weight heparin (LMWH) on tissue factor (TF) expression and activity in five cell lines from variou... Read More about Low molecular weight heparin downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-κB.

Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer (2011)
Journal Article
Ettelaie, C., Gardiner, E., Maraveyas, A., Bozas, G., Fyfe, D., Lofts, F., Propper, D., Roy, R., Sgouros, J., Waters, J., & Wedgwood, K. (2012). Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. European Journal of Cancer, 48(9), 1283-1292. https://doi.org/10.1016/j.ejca.2011.10.017

Background: Annualised figures show an up to 7-fold higher incidence of vascular thromboembolism (VTE) in patients with advanced pancreatic cancer (APC) compared to other common malignancies. Concurrent VTE has been shown to confer a worse overall pr... Read More about Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.

Plasma tissue factor, tissue factor pathway inhibitor and restenosis following femoropopliteal percutaneous transluminal angioplasty in claudicants (2011)
Thesis
Ray, B. Plasma tissue factor, tissue factor pathway inhibitor and restenosis following femoropopliteal percutaneous transluminal angioplasty in claudicants. (Thesis). University of Hull. https://hull-repository.worktribe.com/output/4211926

Introduction: The primary goal in the management of intermittent claudication is to decrease cardiovascular morbidity and mortality by disease modifying therapy. However percutaneous transluminal angioplasty (PTA) is often performed to improve limb r... Read More about Plasma tissue factor, tissue factor pathway inhibitor and restenosis following femoropopliteal percutaneous transluminal angioplasty in claudicants.

Low molecular weight heparin suppresses tissue factor-mediated cancer cell invasion and migration in vitro (2011)
Journal Article
Ettelaie, C., Fountain, D., Collier, M. E. W., Beeby, E., Xiao, Y. P., & Maraveyas, A. (2011). Low molecular weight heparin suppresses tissue factor-mediated cancer cell invasion and migration in vitro. Experimental and Therapeutic Medicine, 2(2), 363-367. https://doi.org/10.3892/etm.2011.211

Elevated expression of tissue factor (TF) has been associated with an increased risk of thrombosis in the majority of cancers. Moreover, treatment of cancer patients with low molecular weight heparin (LMWH) appears to have beneficial effects that rea... Read More about Low molecular weight heparin suppresses tissue factor-mediated cancer cell invasion and migration in vitro.